← 產業報告目錄

Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service (Consumables, Instruments), Test Type (Follow-up, Co-testing, Primary HPV), Technology (MDx, Cytology), Application (Vaginal, Cervical), Care Setting - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-10-04頁數 282報告編號 MD4083

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The HPV testing and Pap test market is valued at an estimated USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, at a CAGR of 10.0% during the forecast period. The rising awareness of cervical cancer and the importance of timely screening is significantly boosting the HPV testing and Pap test market. Public health campaigns, government screening initiatives, and educational efforts are making women more informed about the risks associated with HPV infection and the critical role of early detection. This heightened awareness is leading to greater participation in routine screening programs, directly fueling the demand for both HPV and Pap tests. Support from healthcare providers, advocacy groups, and non-profit organizations further reinforces preventive screening as a key component of women’s healthcare. As more women gain access to information and resources about screening, test volumes are expected to rise steadily, driving sustained market growth and strengthening the role of HPV and Pap testing in reducing cervical cancer incidence worldwide. “By product & service, the consumables segment dominated the HPV testing and Pap test market in 2024.” Based on product & service, the HPV testing and Pap test market is segmented into consumables, instruments, and services. In 2024, consumables accounted for the largest share of the market. This dominance is driven by the widespread use of reagents, collection kits, and assay consumables that are essential for both HPV and Pap testing on a recurring basis. The increasing adoption of HPV screening programs, coupled with the expansion of cervical cancer prevention initiatives, has created steady demand for these products. Consumables play a critical role in ensuring accuracy and reproducibility of test results, which is reinforced by regulatory guidelines that mandate standardized testing protocols. Moreover, the growing shift toward molecular-based HPV assays and automated cytology platforms has further increased the reliance on specialized consumables. The recurring nature of consumable usage, compared to one-time investments in instruments, positions this segment as the largest revenue contributor in the HPV testing and Pap test market. “By application, the vaginal cancer screening segment is projected to achieve the highest growth during the forecast period.” By application, the HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. While cervical cancer screening currently accounts for the majority of testing volumes due to its high prevalence and established screening guidelines, vaginal cancer screening is expected to witness the fastest growth during the forecast period. This growth is primarily driven by increasing awareness of vaginal cancers, improvements in diagnostic sensitivity of HPV tests, and a gradual expansion of screening practices beyond cervical cancer. Rising research efforts and clinical recommendations supporting HPV testing for broader gynecologic cancer detection are also contributing to the adoption of vaginal cancer screening. Although it remains a relatively smaller segment today, the potential for early detection and improved patient outcomes is likely to accelerate demand, positioning vaginal cancer screening as a key growth area in the HPV testing and Pap test market. “The Asia Pacific is projected to be the fastest-growing regional market during the forecast period.” The market for HPV testing and Pap tests is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to experience the fastest growth in the HPV testing and Pap test market during the forecast period. Rapid urbanization, improving healthcare infrastructure, and increasing access to diagnostic facilities are expanding screening opportunities across the region. Government-led initiatives and public health campaigns in countries such as China, India, and Southeast Asian nations are actively promoting cervical cancer awareness and early detection programs. The rising prevalence of HPV infections and growing concerns about women’s health are driving the adoption of HPV and Pap testing. Additionally, market players are introducing cost-effective and high-throughput testing solutions tailored to local needs, further accelerating adoption. The combination of expanding healthcare access, regulatory support, and rising patient awareness positions the Asia Pacific as the fastest-growing regional segment in the global HPV testing and Pap test market. Breakdown of the profiles of primary participants in the HPV testing and Pap test market: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: C-level Executives (27%), Director-level Executives (18%), and Others (55%) • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) The key players in the HPV testing and Pap test market are Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Danaher Corporation (US), Abbott (US), Seegene Inc. (South Korea), SD Biosensor, INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, Inc. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain), Atila Biosystems (US), Yaneng BIOscience (Shenzhen) Co., Ltd. (China), Xiamen Zeesan Biotech Co., Ltd. (China), Advanced Molecular Diagnostics (AMD) (UK), Mylab Discovery Solutions Pvt. Ltd. (India), Sacace Biotechnologies Srl (Italy), Jiangsu Mole Bioscience Co., Ltd. (China), HANGZHOU ALLTEST BIOTECH CO., LTD. (China), Hangzhou Tongzhou Biotechnology Co., Ltd. (China), and Nanjing Liming Biological Products Co., Ltd. (China). Research Coverage: This research report categorizes the HPV testing and Pap test market by product & service (consumables, instruments, and services), test type [HPV testing (primary HPV testing, co-testing, and follow-up HPV testing) and Pap tests], technology (molecular diagnostics, immunodiagnostics, and cytology), application (cervical cancer screening and vaginal cancer screening), care setting (hospitals, diagnostic laboratories, and physicians’ offices & clinics), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the HPV testing and Pap test market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. Competitive analysis of upcoming startups in the HPV testing and Pap test market ecosystem is covered in this report. Reasons to buy this report: The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (rising HPV cases and subsequent increase in cervical cancer, growing awareness of cervical cancer screening programs, and increasing R&D funding initiatives on cervical cancer prevention), opportunities (regulatory guidelines for cervical cancer screening and innovative improvements in HPV tests), restraints (growing awareness of HPV vaccinations), and challenges (uncertain reimbursement scenario, stringent regulatory & legal requirements, and operational barriers) influencing the growth of the HPV testing and Pap test market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches/approvals in the HPV testing and Pap test market. • Market Development: Comprehensive information about lucrative markets across varied regions • Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the HPV testing and Pap test market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), and Danaher Corporation (US).
目錄 Table of Contents
1 INTRODUCTION 28 1.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 STUDY SCOPE 29 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 29 1.3.2 INCLUSIONS AND EXCLUSIONS 30 1.3.3 YEARS CONSIDERED 31 1.4 CURRENCY CONSIDERED 31 1.5 STAKEHOLDERS 31 1.6 SUMMARY OF CHANGES 32 2 RESEARCH METHODOLOGY 33 2.1 RESEARCH DATA 33 2.2 RESEARCH APPROACH 33 2.2.1 SECONDARY DATA 34 2.2.1.1 Key secondary sources 34 2.2.1.2 Key data from secondary sources 34 2.2.2 PRIMARY DATA 35 2.2.2.1 Primary sources 36 2.2.2.2 Key data from primary sources 36 2.2.2.3 Key industry insights 38 2.2.2.4 Breakdown of primary interviews 38 2.3 MARKET SIZE ESTIMATION 39 2.3.1 BOTTOM-UP APPROACH 40 2.3.1.1 Company revenue estimation approach 40 2.3.1.2 Presentations of companies and primary interviews 40 2.3.1.3 Growth forecast 41 2.3.1.4 CAGR projections 41 2.3.1.5 Epidemiology-based test volume estimation approach 42 2.3.2 TOP-DOWN APPROACH 42 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 44 2.5 MARKET SHARE ASSESSMENT 45 2.6 RESEARCH ASSUMPTIONS 45 2.7 RESEARCH LIMITATIONS 45 2.8 RISK ASSESSMENT 46 3 EXECUTIVE SUMMARY 47   4 PREMIUM INSIGHTS 52 4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW 52 4.2 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 52 4.3 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030 53 4.4 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030 53 4.5 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030 54 4.6 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030 54 4.7 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55 5 MARKET OVERVIEW 56 5.1 INTRODUCTION 56 5.2 MARKET DYNAMICS 56 5.2.1 DRIVERS 57 5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer 57 5.2.1.2 Growing awareness about cervical cancer screening programs 58 5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention 59 5.2.2 RESTRAINTS 59 5.2.2.1 Growing awareness and adoption of HPV vaccination 59 5.2.3 OPPORTUNITIES 60 5.2.3.1 Regulatory guidelines for cervical cancer screening 60 5.2.3.2 Innovative improvements in HPV tests 61 5.2.4 CHALLENGES 61 5.2.4.1 Uncertain reimbursement scenario 61 5.2.4.2 Stringent regulatory and legal requirements 62 5.2.4.3 Operational barriers 62 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 62 5.4 PRICING ANALYSIS 63 5.4.1 AVERAGE SELLING PRICE TREND OF HPV AND PAP TESTS 63 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 64 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION 65 5.5 VALUE CHAIN ANALYSIS 65 5.6 SUPPLY CHAIN ANALYSIS 67 5.7 ECOSYSTEM ANALYSIS 68 5.8 INVESTMENT AND FUNDING SCENARIO 69 5.9 TECHNOLOGY ANALYSIS 70 5.9.1 KEY TECHNOLOGIES 70 5.9.1.1 Molecular diagnostics 70 5.9.2 COMPLEMENTARY TECHNOLOGIES 71 5.9.2.1 Cytology 71 5.9.3 ADJACENT TECHNOLOGIES 71 5.9.3.1 Immunodiagnostics 71 5.10 KEY CONFERENCES AND EVENTS, 2025–2026 72 5.11 PATENT ANALYSIS 73 5.12 TRADE ANALYSIS 75 5.12.1 IMPORT DATA FOR HS CODE 3822 75 5.12.2 EXPORT DATA FOR HS CODE 3822 76 5.13 CASE STUDY ANALYSIS 77 5.13.1 CASE STUDY 1: UTILIZATION OF HUMAN PAPILLOMAVIRUS TESTING FOR CERVICAL CANCER SCREENING IN THAILAND 77 5.13.2 CASE STUDY 2: IMPLEMENTATION OF HUMAN PAPILLOMAVIRUS PRIMARY SCREENING OF CERVICAL CANCER IN BRITISH COLUMBIA 78 5.13.3 CASE STUDY 3: COMPARATIVE EVALUATION OF HPV SELF-SAMPLING IN INDIA 78 5.14 REGULATORY LANDSCAPE 79 5.14.1 REGULATORY FRAMEWORK 79 5.14.1.1 NORTH AMERICA 79 5.14.1.1.1 US 79 5.14.1.1.2 Canada 79 5.14.1.2 Europe 79 5.14.1.2.1 Germany 80 5.14.1.2.2 UK 80 5.14.1.2.3 France 81 5.14.1.2.4 Italy 81 5.14.1.3 Asia Pacific 81 5.14.1.3.1 China 81 5.14.1.3.2 Japan 81 5.14.1.3.3 India 82 5.14.1.4 Latin America 82 5.14.1.4.1 Brazil 82 5.14.1.4.2 Mexico 83 5.14.1.5 Middle East 83 5.14.1.6 Africa 83 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 5.15 PORTER’S FIVE FORCES ANALYSIS 85 5.15.1 BARGAINING POWER OF BUYERS 87 5.15.2 BARGAINING POWER OF SUPPLIERS 87 5.15.3 THREAT OF NEW ENTRANTS 87 5.15.4 THREAT OF SUBSTITUTES 87 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 87 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 88 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 88 5.16.2 BUYING CRITERIA 88   5.17 IMPACT OF AI/GENERATIVE AI ON HPV TESTING AND PAP TEST MARKET 89 5.17.1 INTRODUCTION 89 5.17.2 MARKET POTENTIAL OF AI 90 5.17.3 AI USE CASES 91 5.17.4 KEY COMPANIES IMPLEMENTING AI 91 5.17.5 FUTURE OF AI IN HPV TESTING AND PAP TEST MARKET 92 5.18 IMPACT OF 2025 US TARIFFS ON HPV TESTING AND PAP TEST MARKET 92 5.18.1 INTRODUCTION 92 5.18.2 KEY TARIFF RATES 93 5.18.3 PRICE IMPACT ANALYSIS 93 5.18.4 IMPACT ON COUNTRY/REGION 94 5.18.4.1 North America 94 5.18.4.2 Europe 94 5.18.4.3 Asia Pacific 94 5.18.5 IMPACT ON END-USE INDUSTRIES 94 5.18.5.1 Hospitals 94 5.18.5.2 Diagnostic laboratories 95 5.18.5.3 Physicians’ offices & clinics 95 6 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE 96 6.1 INTRODUCTION 97 6.2 CONSUMABLES 97 6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH 97 6.3 INSTRUMENTS 99 6.3.1 INCREASING ADOPTION OF AUTOMATED DIAGNOSTIC SYSTEMS TO DRIVE GROWTH 99 6.4 SERVICES 100 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND 100 7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE 102 7.1 INTRODUCTION 103 7.2 HPV TESTING 103 7.2.1 PRIMARY HPV TESTING 107 7.2.1.1 Test sensitivity and accuracy to drive growth 107 7.2.2 FOLLOW-UP HPV TESTING 109 7.2.2.1 Irregular Pap test results to drive adoption 109 7.2.3 CO-TESTING 112 7.2.3.1 Co-testing to drive rapid detection results for cervical cancer 112 7.3 PAP TESTS 114 7.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET 114   8 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY 117 8.1 INTRODUCTION 118 8.2 MOLECULAR DIAGNOSTICS 118 8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN HPV DETECTION TO DRIVE MARKET GROWTH 118 8.3 IMMUNODIAGNOSTICS 121 8.3.1 COST BENEFITS OF IMMUNOASSAYS TO BOOST DEMAND 121 8.4 CYTOLOGY 124 8.4.1 AUTOMATION AND DIGITAL IMAGING TO DRIVE ADOPTION 124 9 HPV TESTING AND PAP TEST MARKET, BY APPLICATION 127 9.1 INTRODUCTION 128 9.2 CERVICAL CANCER SCREENING 128 9.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET 128 9.3 VAGINAL CANCER SCREENING 133 9.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET 133 10 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING 136 10.1 INTRODUCTION 137 10.2 HOSPITALS 137 10.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET 137 10.3 DIAGNOSTIC LABORATORIES 140 10.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET 140 10.4 PHYSICIANS’ OFFICES & CLINICS 143 10.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH 143 11 HPV TESTING AND PAP TEST MARKET, BY REGION 146 11.1 INTRODUCTION 147 11.2 NORTH AMERICA 148 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 152 11.2.2 US 153 11.2.2.1 Rising government initiatives for cervical cancer testing to expedite growth 153 11.2.3 CANADA 155 11.2.3.1 Growing awareness of cervical cancer screening to support growth 155 11.3 EUROPE 157 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 161 11.3.2 GERMANY 161 11.3.2.1 Established healthcare infrastructure and rising healthcare spending to promote growth 161 11.3.3 UK 163 11.3.3.1 Rising focus on research projects for specific cancers to contribute to growth 163 11.3.4 FRANCE 165 11.3.4.1 High incidence of cervical cancer and associated investments in genomics to stimulate growth 165 11.3.5 ITALY 167 11.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to boost market 167 11.3.6 SPAIN 169 11.3.6.1 Increasing research on cancer diagnostics to accelerate growth 169 11.3.7 REST OF EUROPE 171 11.4 ASIA PACIFIC 174 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 178 11.4.2 CHINA 178 11.4.2.1 Growing public access to modern healthcare to propel market 178 11.4.3 JAPAN 181 11.4.3.1 Rising demand for technologically advanced cervical cancer screening tests to facilitate growth 181 11.4.4 INDIA 183 11.4.4.1 Expanding healthcare access and high cervical cancer burden to drive market 183 11.4.5 REST OF ASIA PACIFIC 185 11.5 LATIN AMERICA 188 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 191 11.5.2 BRAZIL 192 11.5.2.1 Universal healthcare access to speed up growth 192 11.5.3 MEXICO 194 11.5.3.1 Improved access to healthcare to sustain growth 194 11.5.4 REST OF LATIN AMERICA 196 11.6 MIDDLE EAST & AFRICA 199 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 202 11.6.2 SAUDI ARABIA 202 11.6.2.1 Rising government healthcare expenditure to augment growth 202 11.6.3 UAE 205 11.6.3.1 Increasing emphasis on healthy lifestyles and quality of life to encourage growth 205 11.6.4 REST OF MIDDLE EAST & AFRICA 207   12 COMPETITIVE LANDSCAPE 210 12.1 INTRODUCTION 210 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 210 12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET 210 12.3 REVENUE ANALYSIS, 2022–2024 212 12.4 MARKET SHARE ANALYSIS, 2024 213 12.5 COMPANY VALUATION AND FINANCIAL METRICS 215 12.5.1 COMPANY VALUATION 215 12.5.2 FINANCIAL METRICS 216 12.6 BRAND/PRODUCT COMPARISON 216 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 217 12.7.1 STARS 217 12.7.2 EMERGING LEADERS 217 12.7.3 PERVASIVE PLAYERS 217 12.7.4 PARTICIPANTS 217 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 219 12.7.5.1 Company footprint 219 12.7.5.2 Region footprint 220 12.7.5.3 Product & service footprint 220 12.7.5.4 Test type footprint 221 12.7.5.5 Technology footprint 221 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 222 12.8.1 PROGRESSIVE COMPANIES 222 12.8.2 RESPONSIVE COMPANIES 222 12.8.3 DYNAMIC COMPANIES 222 12.8.4 STARTING BLOCKS 222 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 224 12.8.5.1 Detailed list of key startups/SMEs 224 12.8.5.2 Competitive benchmarking of key startups/SMEs 225 12.9 COMPETITIVE SCENARIO 226 12.9.1 PRODUCT LAUNCHES AND APPROVALS 226 12.9.2 DEALS 227 12.9.3 EXPANSIONS 228 13 COMPANY PROFILES 229 13.1 KEY PLAYERS 229 13.1.1 HOLOGIC, INC. 229 13.1.1.1 Business overview 229 13.1.1.2 Products offered 230 13.1.1.3 MnM view 231   13.1.1.3.1 Right to win 231 13.1.1.3.2 Strategic choices 231 13.1.1.3.3 Weaknesses and competitive threats 231 13.1.2 BECTON, DICKINSON AND COMPANY (BD) 232 13.1.2.1 Business overview 232 13.1.2.2 Products offered 233 13.1.2.3 Recent developments 234 13.1.2.3.1 Product launches and approvals 234 13.1.2.3.2 Deals 234 13.1.2.3.3 Expansions 235 13.1.2.4 MnM view 236 13.1.2.4.1 Right to win 236 13.1.2.4.2 Strategic choices 236 13.1.2.4.3 Weaknesses and competitive threats 236 13.1.3 F. HOFFMANN-LA ROCHE LTD. 237 13.1.3.1 Business overview 237 13.1.3.2 Products offered 238 13.1.3.3 Recent developments 239 13.1.3.3.1 Product launches and approvals 239 13.1.3.4 MnM view 239 13.1.3.4.1 Right to win 239 13.1.3.4.2 Strategic choices 240 13.1.3.4.3 Weaknesses and competitive threats 240 13.1.4 QIAGEN 241 13.1.4.1 Business overview 241 13.1.4.2 Products offered 242 13.1.4.3 Recent developments 243 13.1.4.3.1 Expansions 243 13.1.4.4 MnM view 243 13.1.4.4.1 Right to win 243 13.1.4.4.2 Strategic choices 244 13.1.4.4.3 Weaknesses and competitive threats 244 13.1.5 DANAHER CORPORATION 245 13.1.5.1 Business overview 245 13.1.5.2 Products offered 246 13.1.5.3 MnM view 247 13.1.5.3.1 Right to win 247 13.1.5.3.2 Strategic choices 247 13.1.5.3.3 Weaknesses and competitive threats 247   13.1.6 ABBOTT 248 13.1.6.1 Business overview 248 13.1.6.2 Products offered 249 13.1.6.3 Recent developments 250 13.1.6.3.1 Product launches and approvals 250 13.1.6.3.2 Deals 250 13.1.7 SEEGENE INC. 251 13.1.7.1 Business overview 251 13.1.7.2 Products offered 252 13.1.7.3 Recent developments 253 13.1.7.3.1 Product launches and approvals 253 13.1.7.3.2 Deals 253 13.1.8 SD BIOSENSOR, INC. 255 13.1.8.1 Business overview 255 13.1.8.2 Products offered 256 13.1.9 SANSURE BIOTECH INC. 257 13.1.9.1 Business overview 257 13.1.9.2 Products offered 257 13.1.9.3 Recent developments 258 13.1.9.3.1 Product launches and approvals 258 13.1.9.3.2 Deals 258 13.1.10 ACON LABORATORIES, INC. 259 13.1.10.1 Business overview 259 13.1.10.2 Products offered 259 13.2 OTHER PLAYERS 260 13.2.1 MOLBIO DIAGNOSTICS LIMITED 260 13.2.2 AB ANALITICA S.R.L. 261 13.2.3 CERTEST BIOTEC 262 13.2.4 ATILA BIOSYSTEMS 263 13.2.5 TELLGEN CORPORATION 264 13.2.6 DAAN GENE CO., LTD. 265 13.2.7 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD. 266 13.2.8 ANATOLIA GENEWORKS 267 13.2.9 YANENG BIOSCIENCE (SHENZHEN) CO., LTD. 268 13.2.10 XIAMEN ZEESAN BIOTECH CO., LTD. 269 13.2.11 ADVANCED MOLECULAR DIAGNOSTICS (AMD) 270 13.2.12 MYLAB DISCOVERY SOLUTIONS PVT. LTD. 270 13.2.13 SACACE BIOTECHNOLOGIES SRL 271 13.2.14 JIANGSU MOLE BIOSCIENCE CO., LTD. 272 13.2.15 HANGZHOU ALLTEST BIOTECH CO., LTD. 272 13.2.16 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD. 273 13.2.17 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD. 273 14 APPENDIX 274 14.1 DISCUSSION GUIDE 274 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 278 14.3 CUSTOMIZATION OPTIONS 280 14.4 RELATED REPORTS 280 14.5 AUTHOR DETAILS 281
圖表清單 List of Tables & Figures
TABLE 1 HPV TESTING AND PAP TEST MARKET: INCLUSIONS AND EXCLUSIONS 30 TABLE 2 HPV TESTING AND PAP TEST MARKET: KEY DATA FROM PRIMARY SOURCES 36 TABLE 3 HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT ANALYSIS 46 TABLE 4 ESTIMATED NUMBER OF NEW CASES OF CERVICAL CANCER, BY REGION, 2022 VS. 2030 58 TABLE 5 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, 2023–2025 (USD) 63 TABLE 6 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, BY REGION (USD) 64 TABLE 7 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY KEY PLAYER, 2023–2025 (USD) 64 TABLE 8 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY REGION, 2023–2025 (USD) 65 TABLE 9 HPV TESTING AND PAP TEST MARKET: ROLE OF COMPANIES IN ECOSYSTEM 69 TABLE 10 HPV TESTING AND PAP TEST MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 72 TABLE 11 HPV TESTING AND PAP TEST MARKET: LIST OF MAJOR PATENTS, 2023–2025 74 TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 76 TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 77 TABLE 14 CLASSIFICATION OF IVD DEVICES IN EUROPE 80 TABLE 15 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 82 TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 21 HPV TESTING AND PAP TEST MARKET: IMPACT OF PORTER’S FIVE FORCES 86 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 88 TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 89 TABLE 24 RECIPROCAL TARIFF RATES ADJUSTED BY US 93 TABLE 25 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 97 TABLE 26 KEY CONSUMABLES AVAILABLE IN MARKET 98 TABLE 27 HPV TESTING AND PAP TEST CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 28 KEY INSTRUMENTS AVAILABLE IN MARKET 100 TABLE 29 HPV TESTING AND PAP TEST INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 30 HPV TESTING AND PAP TEST SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 31 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 103 TABLE 32 KEY HPV TESTING PRODUCTS AVAILABLE IN MARKET 104 TABLE 33 HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 104 TABLE 34 HPV TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 35 NORTH AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 36 EUROPE: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 37 ASIA PACIFIC: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 38 LATIN AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 39 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 40 PRIMARY HPV TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 41 NORTH AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 42 EUROPE: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 43 ASIA PACIFIC: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 44 LATIN AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 45 MIDDLE EAST & AFRICA: PRIMARY HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 46 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 47 NORTH AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 48 EUROPE: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 49 ASIA PACIFIC: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 50 LATIN AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 51 MIDDLE EAST & AFRICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 52 CO-TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 53 NORTH AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 54 EUROPE: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 55 ASIA PACIFIC: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 56 LATIN AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 57 MIDDLE EAST & AFRICA: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 58 KEY PAP TESTS AVAILABLE IN MARKET 114 TABLE 59 PAP TESTS MARKET, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 60 NORTH AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 61 EUROPE: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 62 ASIA PACIFIC: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 63 LATIN AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 64 MIDDLE EAST & AFRICA: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 65 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 118 TABLE 66 KEY MOLECULAR DIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET 119 TABLE 67 HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 68 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 69 EUROPE: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 70 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 71 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 72 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 73 KEY IMMUNODIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET 122 TABLE 74 HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 75 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 76 EUROPE: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 77 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 78 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 79 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 80 HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 81 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 82 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 83 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 84 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 85 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 86 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 128 TABLE 87 KEY HPV TESTING AND PAP TESTS FOR CERVICAL CANCER SCREENING AVAILABLE IN MARKET 130 TABLE 88 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 89 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 90 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 91 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 92 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 93 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 94 KEY HPV TESTING AND PAP TESTS FOR VAGINAL CANCER SCREENING AVAILABLE IN MARKET 133 TABLE 95 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 96 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 97 EUROPE: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 98 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 99 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 100 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 101 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 137 TABLE 102 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 103 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 104 EUROPE: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 105 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 106 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 107 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 108 HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 109 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 110 EUROPE: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 111 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 112 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 113 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 114 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 115 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 116 EUROPE: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 117 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 118 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 119 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 120 PROJECTED CERVICAL CANCER CASES, BY COUNTRY, 2022 VS. 2030 147 TABLE 121 HPV TESTING AND PAP TEST MARKET, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 122 TOTAL NUMBER OF HPV TESTS CONDUCTED, BY REGION, 2023–2030 (MILLION UNIT) 148 TABLE 123 TOTAL NUMBER OF PAP TESTS CONDUCTED, BY REGION, 2023–2030 (MILLION UNIT) 148 TABLE 124 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 150 TABLE 125 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 126 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 150 TABLE 127 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 151 TABLE 128 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 151 TABLE 129 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 151 TABLE 130 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 152 TABLE 131 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 152 TABLE 132 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 153 TABLE 133 US: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 134 US: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 154 TABLE 135 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 154 TABLE 136 US: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 155 TABLE 137 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 156 TABLE 138 CANADA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 139 CANADA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 156 TABLE 140 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 157 TABLE 141 CANADA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 157 TABLE 142 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 143 EUROPE: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 159 TABLE 144 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 159 TABLE 145 EUROPE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 146 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 160 TABLE 147 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 160 TABLE 148 EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 160 TABLE 149 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 162 TABLE 150 GERMANY: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 151 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 162 TABLE 152 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 163 TABLE 153 GERMANY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 163 TABLE 154 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 164 TABLE 155 UK: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 164 TABLE 156 UK: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 164 TABLE 157 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 165 TABLE 158 UK: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 165 TABLE 159 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 166 TABLE 160 FRANCE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 161 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 166 TABLE 162 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 167 TABLE 163 FRANCE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 167 TABLE 164 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 168 TABLE 165 ITALY: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 166 ITALY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 168 TABLE 167 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 169 TABLE 168 ITALY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 169 TABLE 169 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 170 TABLE 170 SPAIN: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 171 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 170 TABLE 172 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 171 TABLE 173 SPAIN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 171 TABLE 174 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 172 TABLE 175 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 176 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 173 TABLE 177 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 173 TABLE 178 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 173 TABLE 179 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 175 TABLE 180 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 181 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 176 TABLE 182 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 176 TABLE 183 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 184 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 177 TABLE 185 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 177 TABLE 186 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 178 TABLE 187 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 179 TABLE 188 CHINA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 189 CHINA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 180 TABLE 190 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 180 TABLE 191 CHINA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 180 TABLE 192 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 181 TABLE 193 JAPAN: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 194 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 182 TABLE 195 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182 TABLE 196 JAPAN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 183 TABLE 197 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 184 TABLE 198 INDIA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 199 INDIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 184 TABLE 200 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 201 INDIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 185 TABLE 202 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 186 TABLE 203 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 204 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 187 TABLE 205 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187 TABLE 206 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 187 TABLE 207 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 189 TABLE 208 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 209 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 189 TABLE 210 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 190 TABLE 211 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 212 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 190 TABLE 213 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 191 TABLE 214 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 191 TABLE 215 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 192 TABLE 216 BRAZIL: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 217 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 193 TABLE 218 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 193 TABLE 219 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 194 TABLE 220 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 195 TABLE 221 MEXICO: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 222 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 195 TABLE 223 MEXICO: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 196 TABLE 224 MEXICO: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 196 TABLE 225 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 197 TABLE 226 REST OF LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 227 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 198 TABLE 228 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 229 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 198 TABLE 230 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 199 TABLE 231 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 232 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 200 TABLE 233 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 200 TABLE 234 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 235 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 201 TABLE 236 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 201 TABLE 237 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 202 TABLE 238 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 203 TABLE 239 SAUDI ARABIA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 203 TABLE 240 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 204 TABLE 241 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 204 TABLE 242 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 204 TABLE 243 UAE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 205 TABLE 244 UAE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 206 TABLE 245 UAE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 206 TABLE 246 UAE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 247 UAE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 207 TABLE 248 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 208 TABLE 249 REST OF MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 250 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 208 TABLE 251 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 252 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 209 TABLE 253 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, JANUARY 2022−SEPTEMBER 2025 210 TABLE 254 HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION 214 TABLE 255 HPV TESTING AND PAP TEST MARKET: REGION FOOTPRINT 220 TABLE 256 HPV TESTING AND PAP TEST MARKET: PRODUCT & SERVICE FOOTPRINT 220 TABLE 257 HPV TESTING AND PAP TEST MARKET: TEST TYPE FOOTPRINT 221 TABLE 258 HPV TESTING AND PAP TEST MARKET: TECHNOLOGY FOOTPRINT 221 TABLE 259 HPV TESTING AND PAP TEST MARKET: DETAILED LIST OF KEY STARTUPS/SMES 224 TABLE 260 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE AND TEST TYPE 225 TABLE 261 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION 225 TABLE 262 HPV TESTING AND PAP TEST MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 226 TABLE 263 HPV TESTING AND PAP TEST MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025 227 TABLE 264 HPV TESTING AND PAP TEST MARKET: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 228 TABLE 265 HOLOGIC, INC.: COMPANY OVERVIEW 229 TABLE 266 HOLOGIC, INC.: PRODUCTS OFFERED 230 TABLE 267 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 232 TABLE 268 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 233 TABLE 269 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 234 TABLE 270 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022–SEPTEMBER 2025 234 TABLE 271 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 235 TABLE 272 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 237 TABLE 273 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 238 TABLE 274 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 239 TABLE 275 QIAGEN: COMPANY OVERVIEW 241 TABLE 276 QIAGEN: PRODUCTS OFFERED 242 TABLE 277 QIAGEN: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 243 TABLE 278 DANAHER CORPORATION: COMPANY OVERVIEW 245 TABLE 279 DANAHER CORPORATION: PRODUCTS OFFERED 246 TABLE 280 ABBOTT: COMPANY OVERVIEW 248 TABLE 281 ABBOTT: PRODUCTS OFFERED 249 TABLE 282 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 250 TABLE 283 ABBOTT: DEALS, JANUARY 2022–SEPTEMBER 2025 250 TABLE 284 SEEGENE INC.: COMPANY OVERVIEW 251 TABLE 285 SEEGENE INC.: PRODUCTS OFFERED 252 TABLE 286 SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 253 TABLE 287 SEEGENE INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 253 TABLE 288 SD BIOSENSOR, INC.: COMPANY OVERVIEW 255 TABLE 289 SD BIOSENSOR, INC.: PRODUCTS OFFERED 256 TABLE 290 SANSURE BIOTECH INC.: COMPANY OVERVIEW 257 TABLE 291 SANSURE BIOTECH INC.: PRODUCTS OFFERED 257 TABLE 292 SANSURE BIOTECH INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 258 TABLE 293 SANSURE BIOTECH INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 258 TABLE 294 ACON LABORATORIES, INC.: COMPANY OVERVIEW 259 TABLE 295 ACON LABORATORIES, INC.: PRODUCTS OFFERED 259 TABLE 296 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW 260 TABLE 297 AB ANALITICA S.R.L.: COMPANY OVERVIEW 261 TABLE 298 CERTEST BIOTEC: COMPANY OVERVIEW 262 TABLE 299 ATILA BIOSYSTEMS: COMPANY OVERVIEW 263 TABLE 300 TELLGEN CORPORATION: COMPANY OVERVIEW 264 TABLE 301 DAAN GENE CO., LTD.: COMPANY OVERVIEW 265 TABLE 302 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.: COMPANY OVERVIEW 266 TABLE 303 ANATOLIA GENEWORKS: COMPANY OVERVIEW 267 TABLE 304 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.: COMPANY OVERVIEW 268 TABLE 305 XIAMEN ZEESAN BIOTECH CO., LTD.: COMPANY OVERVIEW 269 TABLE 306 ADVANCED MOLECULAR DIAGNOSTICS (AMD): COMPANY OVERVIEW 270 TABLE 307 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: COMPANY OVERVIEW 270 TABLE 308 SACACE BIOTECHNOLOGIES SRL: COMPANY OVERVIEW 271 TABLE 309 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW 272 TABLE 310 HANGZHOU ALLTEST BIOTECH CO., LTD.: COMPANY OVERVIEW 272 TABLE 311 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 273 TABLE 312 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.: COMPANY OVERVIEW 273 FIGURE 1 HPV TESTING AND PAP TEST MARKET SEGMENTATION AND REGIONAL SCOPE 29 FIGURE 2 HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN METHODOLOGY 33 FIGURE 3 PRIMARY SOURCES 36 FIGURE 4 KEY INDUSTRY INSIGHTS 38 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39 FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41 FIGURE 9 EPIDEMIOLOGY-BASED TEST VOLUME ESTIMATION APPROACH 42 FIGURE 10 HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH 43 FIGURE 11 DATA TRIANGULATION METHODOLOGY 44 FIGURE 12 HPV TESTING AND PAP TEST MARKET: RESEARCH ASSUMPTIONS 45 FIGURE 13 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 47 FIGURE 14 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 15 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030(USD MILLION) 48 FIGURE 16 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 49 FIGURE 17 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030 (USD MILLION) 50 FIGURE 18 HPV TESTING AND PAP TEST MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 50 FIGURE 19 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET 52 FIGURE 20 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52 FIGURE 21 HPV TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 53 FIGURE 22 MOLECULAR DIAGNOSTICS SEGMENT TO SHOWCASE LARGEST MARKET SHARE DURING FORECAST PERIOD 53 FIGURE 23 CERVICAL CANCER SCREENING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 54 FIGURE 24 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030 54 FIGURE 25 NORTH AMERICAN MARKET TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD 55 FIGURE 26 HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN HPV TESTING AND PAP TEST MARKET 63 FIGURE 28 HPV TESTING AND PAP TEST MARKET: VALUE CHAIN ANALYSIS 66 FIGURE 29 HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS 68 FIGURE 30 HPV TESTING AND PAP TEST MARKET: ECOSYSTEM ANALYSIS 68 FIGURE 31 HPV TESTING AND PAP TEST MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025 70 FIGURE 32 HPV TESTING AND PAP TEST MARKET: PATENT ANALYSIS, JANUARY 2015–DECEMBER 2024 73 FIGURE 33 HPV TESTING AND PAP TEST MARKET: PORTER’S FIVE FORCES ANALYSIS 86 FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 88 FIGURE 35 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 88 FIGURE 36 MARKET POTENTIAL OF AI IN HPV TESTING AND PAP TEST MARKET 90 FIGURE 37 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT 149 FIGURE 38 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT 175 FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, 2022–2024 212 FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET, 2024 213 FIGURE 41 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 215 FIGURE 42 EV/EBITDA OF KEY VENDORS 216 FIGURE 43 HPV TESTING AND PAP TEST MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 216 FIGURE 44 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 218 FIGURE 45 HPV TESTING AND PAP TEST MARKET: COMPANY FOOTPRINT 219 FIGURE 46 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 223 FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT 230 FIGURE 48 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 233 FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 238 FIGURE 50 QIAGEN: COMPANY SNAPSHOT 242 FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT 246 FIGURE 52 ABBOTT: COMPANY SNAPSHOT 249 FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT 252 FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT 255

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們